Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;94(3):211-213.
doi: 10.1097/QAI.0000000000003282.

Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada

Maxime J Billick  1 , Karla N Fisher  2 , Samantha Myers  3 , Darrell H S Tan  1   3 , Isaac I Bogoch  1   2   4
Affiliations

Brief Report: Outcomes of Individuals Using HIV Postexposure Prophylaxis-In-Pocket ("PIP") for Low-Frequency, High-Risk Exposures in Toronto, Canada

Maxime J Billick et al. J Acquir Immune Defic Syndr. .

Abstract

Background: HIV postexposure prophylaxis-in-pocket ("PIP") is a self-initiated, event-driven HIV prevention modality for individuals with a low frequency of HIV exposures.

Methods: A cohort of 111 patients using PIP as their primary HIV prevention modality was longitudinally evaluated for PIP self-initiation, HIV and sexual transmitted infections, and switching to other HIV prevention modalities between February 2016 and December 2022.

Results: A total of 111 patients had 178.7 cumulative patient-years of PIP use. PIP was self-initiated 69 times by 35 (31.5%) individuals, with 0 HIV seroconversions identified. Thirty four individuals (30.6%) transitioned from PIP to pre-exposure prophylaxis and 33 individuals (29.7%) switched from pre-exposure prophylaxis to PIP.

Conclusions: PIP is a useful addition to other pharmacologic HIV prevention tools, and may help prevent infection in those with a lower frequency of unanticipated HIV exposures.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Tan DHS, Hull MW, Yoong D, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. Can Med Assoc J. 2017;189:E1448–E1458.
    1. Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prepguidelines-2021.pdf; 2021. Accessed July 4, 2023.
    1. Bogoch II, Scully EP, Zachary KC, et al. Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis. Clin Infect Dis. 2014;58:1618–1624.
    1. Amato AT, Kiffer C, Ben K, et al. Barriers to PrEP uptake in two spirit, gay, bisexual, trans and queer men, and non-binary people in Canada: an analysis considering indigeneity, ethnoracial and gender-diverse identities within a community-based health survey. ScienceOpen Posters. January 24, 2024. Available at: https://www.cbrc.net/barriers_to_prep_uptake. Accessed July 1, 2023.
    1. Tumarkin E, Heendeniya A, Murphy P, et al. Brief report: HIV postexposure prophylaxis-in-pocket (“PIP”) for individuals with low-frequency, high-risk HIV exposures. J Acquir Immune Defic Syndr. 2018;78:20–22.

Publication types

MeSH terms

Substances

Grants and funding